Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium
NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.
About Rain Therapeutics Inc.
Registration Counters Open
ChatGPT: More than just a Machine
ITEXPO #TECHSUPERSHOW Expo Hall Grand Opening